JW Therapeutics: JW Therapeutics gets China NMPA IND clearance for clinical trial of relmacel in patients with moderately or severely refractory SLE
JW Therapeutics, an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that it has received the
Read full article »
JW Therapeutics is a China-based biotechnology company that researches cell-based immunotherapies to treat hematologic malignancies, solid tumors and autoimmune diseases.
Read more